Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

0.3700
-0.0299-7.48%
Post-market: 0.38000.0100+2.70%19:47 EDT
Volume:2.66M
Turnover:1.05M
Market Cap:64.51M
PE:422.86
High:0.4393
Open:0.4189
Low:0.3644
Close:0.3999
Loading ...

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Zacks
·
17 Apr

Seres Therapeutics Approves Reverse Stock Split Plan

TIPRANKS
·
15 Apr

Seres Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
21 Mar

Seres Therapeutics Is Maintained at Sell by Goldman Sachs

Dow Jones
·
15 Mar

Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?

Simply Wall St.
·
14 Mar

Q4 2024 Seres Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Mar

Seres Therapeutics Advances SER-155 Program with FDA Support

TIPRANKS
·
14 Mar

Seres Therapeutics: Strategic Developments and Promising Clinical Data Justify Buy Rating

TIPRANKS
·
14 Mar

Seres Therapeutics reports FY24 EPS (81c), consensus (20c)

TIPRANKS
·
13 Mar

Seres Therapeutics announces anticipated upcoming milestones

TIPRANKS
·
13 Mar

Seres Therapeutics sees cash runway into 1Q26

TIPRANKS
·
13 Mar

Seres Therapeutics Reported Q4 Net Loss From Continuing Operations Of $15.7M, Narrowing From A Year-Ago Loss Of $34.7M

Benzinga
·
13 Mar

BRIEF-Seres Therapeutics FY EPS USD 0

Reuters
·
13 Mar

Seres Therapeutics FY EPS USD 0

THOMSON REUTERS
·
13 Mar

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire
·
13 Mar

Seres Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
05 Mar

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

GlobeNewswire
·
04 Mar

Positive Outlook for Seres Therapeutics: FDA Endorsement and Strategic Study Design Boost Buy Rating

TIPRANKS
·
04 Mar

Seres Therapeutics Inc - FDA Supports Primary Efficacy Endpoint for Ser-155 Study

THOMSON REUTERS
·
03 Mar

Seres Therapeutics Receives Feedback From FDA on Ser-155 Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Development Approach

THOMSON REUTERS
·
03 Mar